Maslow Joel N, Kwon Ijoo, Kudchodkar Sagar B, Kane Deborah, Tadesse Amha, Lee Hyojin, Park Young K, Muthumani Kar, Roberts Christine C
GeneOne Life Science, Inc., Seoul 04500, Republic of Korea.
Department of Medicine, Morristown Medical Center, Morristown, NJ 07960, USA.
Vaccines (Basel). 2023 May 23;11(6):1016. doi: 10.3390/vaccines11061016.
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.
我们重点介绍了在新冠疫情期间DNA疫苗研发方面取得的重大进展。具体而言，我们对已进入2期试验或更后期阶段的DNA疫苗进行了全面综述，包括那些已获得使用授权的疫苗。DNA疫苗在生产速度、热稳定性、安全性和细胞免疫反应方面具有显著优势。根据用户需求和成本，我们比较了在新冠临床试验中使用的三种设备。在这三种设备中，GeneDerm吸引装置具有诸多优势，特别是对于国际疫苗接种运动。因此，DNA疫苗是未来应对大流行的一个有前景的选择。
